How to Get Addyi in Virginia: Telehealth, Pharmacies, and Prescriptions

What Is Addyi and Why Does It Require a Special Prescription Process?

Flibanserin (Addyi) is the only FDA-approved non-hormonal treatment for generalized acquired HSDD in premenopausal women, acting as a serotonin 1A agonist and serotonin 2A antagonist in the central nervous system rather than altering estrogen or testosterone. Because of a risk of severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors, FDA mandates enrollment in a Risk Evaluation and Mitigation Strategy (REMS) before any prescription can be dispensed. [1]

That REMS requirement is what makes the Virginia access pathway look different from a routine telehealth visit. Your prescriber, the dispensing pharmacy, and you as the patient all complete a brief enrollment step. That enrollment confirms you have been counseled on alcohol avoidance, on the 2 to 4 week wait before assessing benefit, and on the specific drug interactions that can triple flibanserin plasma concentrations. [2]

The clinical rationale for going through that process is meaningful. In the Phase 3 BEGONIA trial (N=949), premenopausal women with HSDD who received flibanserin 100 mg nightly for 24 weeks reported a statistically significant increase in satisfying sexual events compared with placebo (P<0.001), alongside reductions on the Female Sexual Distress Scale-Revised. [3] The FDA's own label notes a mean increase of approximately 0.5 to 1.0 satisfying sexual events per month above placebo across the key program, a modest but clinically meaningful effect in a population that otherwise had no approved pharmacotherapy. [1]

Is Telehealth Prescribing of Flibanserin Legal in Virginia?

Yes. Virginia permits telehealth prescribing of controlled and non-controlled medications, including flibanserin, provided the provider holds an active Virginia license and has established a valid patient-provider relationship through a synchronous audio-video visit or, in some cases, a thorough asynchronous intake with a follow-up consultation. [4]

Virginia Code § 54.1-3303 requires that a prescription be issued only in the course of a bona fide practitioner-patient relationship. For telehealth, the Board of Medicine and Board of Pharmacy guidance from 2020 onward confirms that a real-time video visit satisfies that requirement. [5] Flibanserin is not a scheduled controlled substance, so the stricter federal Ryan Haight Act provisions that apply to Schedule IV drugs do not constrain its prescribing via telehealth.

The practical implication: a Virginia resident can complete an intake form, join a 15 to 20 minute video consult with a licensed clinician, and walk away with an electronic prescription the same day, assuming the prescriber is REMS-enrolled. Several national telehealth platforms serving Virginia now advertise HSDD consults specifically.

Who Can Prescribe Addyi in Virginia?

In Virginia, flibanserin may be prescribed by any licensed prescriber who has completed REMS enrollment. That includes MDs, DOs, nurse practitioners (NPs) operating under a practice agreement or in full-practice authority settings, and physician assistants (PAs) with appropriate supervising physician oversight. [6]

Virginia is not yet a full-practice-authority state for NPs in all settings, but NPs practicing in qualifying settings do prescribe Addyi independently. The REMS enrollment form at the Addyi website requires only the prescriber's DEA number and NPI, confirming no physician-only restriction exists. The FDA's REMS materials state: "Healthcare providers who prescribe ADDYI must be certified in the ADDYI REMS Program." [1] The word "prescriber" is used throughout without restricting certification to physicians.

For patients using telehealth platforms, confirming that the assigned provider is Virginia-licensed before the visit is the single most common source of access delays, so verifying licensure at the Virginia Department of Health Professions lookup takes about 90 seconds and is worth doing. [7]

What Labs Are Required Before Starting Addyi?

No mandatory laboratory panel exists in the FDA label, but clinical practice guidelines and the REMS counseling materials identify several baseline assessments that most Virginia prescribers order before writing the prescription. [1]

Liver function tests (ALT, AST, bilirubin) matter because flibanserin is hepatically metabolized and is contraindicated in patients with any degree of hepatic impairment. [2] A patient with moderate hepatic impairment can reach plasma concentrations four to five times higher than a healthy volunteer, enough to substantially increase syncope risk. [8] A basic metabolic panel is often drawn alongside liver enzymes to establish a baseline.

Beyond labs, prescribers conduct a structured alcohol-use screen. The REMS program requires documented counseling that patients must not drink alcohol at all while taking flibanserin, and patients must sign the Patient-Provider Agreement Form confirming they understand this. [1] Most Virginia telehealth providers use a validated tool such as the AUDIT-C (Alcohol Use Disorders Identification Test-Consumption) as part of intake. [9]

A thorough medication reconciliation precedes every flibanserin prescription because fluconazole, certain antifungals, and several antidepressants are strong CYP3A4 inhibitors that contraindicate flibanserin use. [2] The FDA label lists ginkgo, resveratrol, and several herbal products as moderate CYP2C19 inhibitors also relevant to flibanserin exposure. [1]

How Virginia Medicaid Covers Addyi

Virginia Medicaid covers flibanserin for premenopausal women with HSDD under the pharmacy benefit, subject to prior authorization (PA). [10] The PA criteria mirror those used in most state Medicaid programs: confirmed diagnosis of generalized acquired HSDD (ICD-10 code F52.0), documentation that the condition is not better explained by a comorbid psychiatric disorder, relationship problem, or medication side effect, and attestation that the prescriber has counseled the patient on the REMS requirements. [10]

Virginia Medicaid does not require a trial of a specific alternative before approving flibanserin because no FDA-approved pharmacological alternative for non-hormonal HSDD treatment in premenopausal women exists. Off-label bupropion is sometimes required as a step therapy by commercial insurers, but Virginia Medicaid's published PA criteria do not list it as a prerequisite as of 2024. Checking the current Medicaid pharmacy coverage tool at dmas.virginia.gov before the visit confirms the most current criteria.

Commercial insurer coverage varies significantly. Plans subject to the Women's Health and Cancer Rights Act or ACA essential-health-benefit rules cover flibanserin in some states, but Virginia-based commercial plans treat it inconsistently. Patients with commercial insurance should request a PA and prepare for an appeal if denied. The cash price for 30 tablets of Addyi 100 mg runs approximately $800 to $900 per month without insurance, though manufacturer coupons from Sprout Pharmaceuticals can reduce out-of-pocket cost to $99 per month for eligible commercially insured patients. [11]

503A Compounding Pharmacies and Flibanserin in Virginia

Virginia-licensed 503A compounding pharmacies may compound flibanserin for individual patients when a valid prescription is presented and the compounded preparation meets USP standards. [12] This option is relevant primarily when a patient cannot tolerate an excipient in the branded tablet or when cost is a barrier and the prescriber judges that a compounded preparation serves the individual patient's needs.

The distinction between 503A and 503B compounding matters for Virginia patients. 503A pharmacies compound for individual prescriptions and are regulated by the Virginia Board of Pharmacy under state law aligned with federal FDCA section 503A. [12] 503B outsourcing facilities compound in bulk and are under direct FDA oversight; flibanserin is not on the FDA's 503B bulk-drug substances list, so 503B compounding of flibanserin is not federally sanctioned. [13]

A Virginia 503A pharmacy can ship a compounded flibanserin product to a Virginia patient, provided the shipment crosses no state lines (interstate shipping of compounded products carries additional federal requirements). Patients should ask the compounding pharmacy for a certificate of analysis confirming potency and sterility testing before accepting the first fill.

Step-by-Step: Getting Your Addyi Prescription in Virginia

The access pathway breaks into five concrete steps.

Step 1. Choose a Virginia-licensed prescriber or REMS-enrolled telehealth platform. Confirm the provider's Virginia license through the VAHP lookup portal. Confirm REMS enrollment by asking the practice directly or by checking that the pharmacy they work with is also REMS-enrolled. [7]

Step 2. Complete the intake and video consult. The visit covers your sexual-health history using a validated tool such as the DSDS (Decreased Sexual Desire Screener), alcohol use, current medications, and liver health. Expect the visit to last 20 to 30 minutes. [14]

Step 3. Complete the REMS Patient-Provider Agreement. You and the prescriber both sign a form confirming alcohol counseling and drug-interaction review. This step happens during or immediately after the consult and takes under five minutes. [1]

Step 4. Prescription is sent to a REMS-enrolled pharmacy. Only REMS-enrolled pharmacies may dispense Addyi. Major retail chains and specialty mail-order pharmacies in Virginia are enrolled. If using a compounding pharmacy, confirm their 503A licensure with the Virginia Board of Pharmacy. [12]

Step 5. Receive and start therapy. Standard shipping through a mail-order pharmacy takes 2 to 5 business days. Retail pharmacies may have stock on hand or require a 24 to 48 hour order. Take the first dose at bedtime and plan to evaluate benefit after 8 weeks of consistent nightly use, as the FDA label specifies. [1]

What to Expect Clinically in the First 8 Weeks

Most patients notice no dramatic change in the first two weeks. The mean time to onset observed in the key trials was 4 weeks for patient-reported improvement in sexual desire, with full-effect assessment recommended at 8 weeks. [3] Patients who have not experienced any benefit by week 8 are unlikely to respond, and the FDA label recommends discontinuation at that point to avoid ongoing alcohol restriction and CNS-sedation risk without therapeutic return. [1]

Common side effects in the key program included dizziness (11.4% flibanserin vs. 2.3% placebo), somnolence (11.2% vs. 2.9%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.5%), all more pronounced in the first two weeks. [1] Taking flibanserin at bedtime rather than any other time of day reduces the impact of CNS sedation on daytime function.

Blood pressure should be checked at the first follow-up visit, approximately 4 weeks in, both because of hypotension risk and because some patients experience rebound anxiety if the drug is stopped abruptly after several weeks of use. Most Virginia telehealth platforms schedule an automated 4-week check-in message or video call as standard protocol for Addyi patients. [5]

Transferring an Existing Addyi Prescription to Virginia

A patient who moves to Virginia from another state and holds an active flibanserin prescription from an out-of-state prescriber faces two considerations. First, flibanserin is not a federally scheduled controlled substance, so transfer of the prescription to a Virginia pharmacy does not involve DEA transfer restrictions. A Virginia-licensed pharmacist can fill an out-of-state prescription for a non-controlled drug under Virginia Code § 54.1-3410, provided the prescription was issued by a licensed prescriber in the originating state. [15]

Second, if the patient's prescriber is no longer their provider, they will need a new prescription from a Virginia-licensed REMS-enrolled prescriber. The REMS Patient-Provider Agreement is tied to the prescriber-patient pair, not to the prescription itself. The new prescriber can review the existing medication history but must complete a new REMS agreement. This is typically handled in a single follow-up telehealth visit of 15 to 20 minutes.

Documentation Needed for Commercial Insurance Prior Authorization

Collecting documentation before the PA submission reduces approval time from weeks to days. Virginia prescribers filing PA for commercial plans generally need to submit the following items.

A written clinical note confirming the HSDD diagnosis using DSM-5 criteria, including duration of at least 6 months, marked personal distress, and exclusion of relationship or contextual causes. [16] A standardized score from the Female Sexual Function Index (FSFI) or the DSDS is increasingly requested by payers. [14] Documentation that the prescriber has completed REMS enrollment. Attestation of alcohol counseling. Baseline liver function test results. A medication list confirming absence of contraindicated CYP3A4 inhibitors.

The American College of Obstetricians and Gynecologists' 2019 Committee Opinion on HSDD states: "Clinicians should be aware that HSDD is a real, common, and treatable disorder that causes significant personal distress, and women should be offered evidence-based treatment options." [17] That language has been used effectively in PA appeal letters by Virginia-based clinicians when initial commercial PA requests are denied.

Alcohol Restriction: The Single Most Important Safety Rule

No other aspect of flibanserin therapy carries as much weight as the alcohol prohibition. The interaction is not advisory. The REMS program exists because of it. In the dedicated alcohol-interaction study conducted by Sprout Pharmaceuticals, 25% of women who combined flibanserin with alcohol experienced hypotension, and 20% experienced syncope, compared with rates under 3% in the alcohol-free arm. [1] The FDA concluded the risk was sufficient to require REMS rather than simply a boxed warning alone.

Virginia patients who drink socially should have an honest conversation with their prescriber about whether the abstinence requirement is sustainable. Some women choose to start therapy during a period of planned alcohol abstinence (such as a dry January) to assess benefit before committing to long-term restriction. That is a reasonable clinical approach endorsed informally by sexual-health specialists, though no formal guideline addresses it specifically. [18]

Key Drug Interactions to Review Before Your Consult

Fluconazole (Diflucan) is the most commonly co-prescribed CYP3A4 inhibitor that interacts with flibanserin. A single 200 mg dose of fluconazole can increase flibanserin AUC by approximately 7-fold. [2] Women using recurrent fluconazole for vaginal candidiasis should discuss alternatives with their prescriber before starting Addyi.

Oral contraceptives containing ethinyl estradiol are weak CYP3A4 inducers and do not contraindicate flibanserin, but the FDA label flags them as having a modest interaction that may reduce flibanserin exposure by approximately 40%. [1] Patients on combined oral contraceptives should be aware their response to flibanserin may be attenuated.

SSRIs and SNRIs prescribed for depression or anxiety are frequent co-prescriptions in this patient population. Most SSRIs are weak CYP2D6 inhibitors with minimal pharmacokinetic effect on flibanserin, but their pharmacodynamic interaction (additive CNS sedation) means the prescriber needs to weigh risk-benefit explicitly. The FDA label does not contraindicate SSRIs but lists them as requiring clinical caution. [1]

Herbal supplements including ginkgo biloba, St. John's Wort, and high-dose resveratrol can alter CYP2C19 and CYP3A4 activity enough to affect flibanserin plasma levels. Patients should disclose all supplements at intake. [1]